("Cyprotex" or "the Company")
Launch of New Advanced 3D Cardiotoxicity Model
Cyprotex PLC (AIM:CRX), a specialist Contract Research Organisation (CRO), announced today the launch of a new in vitro 3D cellular model for evaluating potential cardiotoxicity. The new model uses human induced pluripotent stem cell (iPSC) derived cardiomyocytes which beat spontaneously in a similar manner to a human heart.
Cardiac hypertrophy is the increase in size and mass of heart muscle. It can be a consequence of many factors including physiological diseases such as high blood pressure or heart valve damage. However, drug-induced cardiac hypertrophy is also a major issue which is often not identified during preclinical pharmaceutical testing. The new 3D model developed by Cyprotex can detect time-dependent hypertrophy following repeat dosing of known cardiotoxins. It has the advantage that it can be tested over prolonged periods, better representing patient dosing regimens. As well as hypertrophy, sophisticated high content imaging techniques are used to monitor a number of other endpoints related to structural damage in the heart.
Dr Anthony Baxter, Cyprotex’s Chief Executive Officer, comments: “Cyprotex have specialist expertise in the field of 3D cellular models. These models are proving valuable in preclinical testing due to their longevity and their physiological relevance to tissues in the body. Further development of our 3D technology is a major focus in our R&D efforts and will enable us to achieve our goal of improving the prediction of human drug-induced toxicity using advanced in vitro models.”
For Further Information
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Office
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1400 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company’s core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe® PK, chemPK™, chemTarget and chemTox, and a range of skin, ocular and endocrine disruption services. For more information, please visit www.cyprotex.com.